<DOC>
	<DOC>NCT00967213</DOC>
	<brief_summary>The purpose of this study is to evaluate changes in preferential hyperacuity perimeter (PHP) and fundus autofluorescence (FAF) in patients with neovascular age-related macular degeneration receiving combination of ranibizumab (LucentisTM) and verteporfin (Visudyne®) therapy</brief_summary>
	<brief_title>Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Signed written informed consent Age ≥ 50 years old Patients with primary active subfoveal CNV secondary to AMD Baseline bestcorrected visual acuity (BCVA) in the study eye was from 20/40 to 20/400 using ETDRS chart Characteristics of AMD lesion predominantly or minimally classic, or occult absence of prior subfoveal treatment for macular disease total lesion size ≤ 9 optic disc areas, with CNV component ≥ 50% of the lesion (unless a serous pigment epithelial detachment was present, in which case &lt; 50% CNV was acceptable) active choroidal neovascularization leakage submacular blood &lt; 50% and subretinal fibrosis &lt; 25% of the total lesion additional eye disease that could compromise VA CNV unrelated to AMD ocular inflammation vitreous hemorrhage retinal hemorrhage (other than AMD related submacular blood) &gt; 1 disc areas intraocular surgery ≤ 1 month before day 0 uncontrolled glaucoma prior treatments with verteporfin PDT laser photocoagulation or other intervention for AMD previous treatment with externalbeam radiation therapy or transpupillary thermotherapy history of vitrectomy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>